Mercaptopurine Anhydrous

Mercaptopurine Anhydrous

SCHEMBL6558420

NC(=O)c1cccnc1.S=c1[nH]cnc2nc[nH]c12

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPAT

The experimentally established mechanism targets of Mercaptopurine Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F7 P08709 1/20 0.58
F3 P13726 1/20 0.58
SARM1 Q6SZW1 1/20 0.58
SIRT2 Q8IXJ6 1/20 0.58
SIRT6 Q8N6T7 1/20 0.58
SIRT1 Q96EB6 1/20 0.58
SIRT3 Q9NTG7 1/20 0.58
SIRT5 Q9NXA8 1/20 0.58
SIRT4 Q9Y6E7 1/20 0.58
MKNK1 Q9BUB5 3/20 0.41
MKNK2 Q9HBH9 2/20 0.41
CYP3A4 P08684 2/20 0.41
ALDH1A1 P00352 2/20 0.41
APP P05067 1/20 0.41
GAA P10253 1/20 0.41
HCAR3 P49019 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41
PIM1 P11309 1/20 0.40
NEK2 P51955 2/20 0.39
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hypoxanthine SCHEMBL472854 0.86 F7 (0.61) F7F3SARM1SIRT2SIRT6
Thioguanine SCHEMBL2314990 0.86 F7 (0.50) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL2564210 0.82 PI4KA (0.55) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL15700 0.82 PI4KA (0.55) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL22748487 0.82 PI4KA (0.55) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL23531102 0.81 PI4KA (0.54) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL11807683 0.81 PI4KA (0.54) F7F3SARM1SIRT2SIRT6
Mercaptopurine Anhydrous SCHEMBL14125533 0.81 F7 (0.54) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL7712108 0.81 PI4KA (0.54) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL1324561 0.81 PI4KA (0.54) F7F3SARM1SIRT2SIRT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040214789-A1 Therapeutics POTTER BARRY V L (GB) 2004-10-28 US claimed
EP-1395267-A2 THERAPEUTIC COMPOSITIONS FOR MODULATING THE IMMUNE RESPONSE IN A MAMMAL AND USE THEREOF UNIVERSITY OF BATH (GB) 2004-03-10 EP claimed
WO-2002098397-A2 THERAPEUTIC COMPOSITIONS FOR MODULATING THE IMMUNE RESPONSE IN A MAMMAL AND USE THEREOF UNIVERSITY OF BATH (GB) 2002-12-12 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214789-A1 Therapeutics CD38, ADCY1, ADCY2 F7 2667/4885F3 3270/4885SARM1 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.